DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Multiple Sclerosis – Kesimpta Drug Quantity Management Policy – Per Days
- Kesimpta® (ofatumumab subcutaneous injection – Novartis)

REVIEW DATE: 05/15/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Kesimpta, a CD20-directed cytolytic antibody, is indicated for the treatment of relapsing forms of **multiple sclerosis** (MS) to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive MS in adults.[1]

Dosing

The recommended dose of Kesimpta is an initial dose of 20 mg by subcutaneous (SC) injection at Week 0, 1, and 2, followed by subsequent doses of 20 mg SC once monthly starting at Week 4.[1]

Availability

Kesimpta is approved as a 20 mg/0.4 mL single-dose prefilled Sensoready pen and a 20 mg/0.4 mL single-dose prefilled syringe.[1] The prefilled syringe is not on the market and therefore, is not currently targeted in this policy.

POLICY STATEMENT

This Drug Quantity Management program has been developed to manage potential premature dose escalation of Kesimpta. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity per 84 Days
Kesimpta® (ofatumumab subcutaneous injection)	20 mg/0.4 mL Sensoready pen	1 pen	3 pens

Multiple Sclerosis – Kesimpta Drug Quantity Management Policy – Per Days product(s) is(are) covered as medically necessary when the following criteria is(are) met. Any other exception is considered not medically necessary.

CRITERIA

1. If the patient is initiating treatment or requires additional induction dosing, approve a one-time override of 4 pens as a 28-day supply at retail or 6 pens as an 84-day supply at home delivery.
Note: This override provides a quantity sufficient for Week 0, 1, 2, and 4 doses at retail or Week 0, 1, 2, 4, 8, and 12 doses at home delivery.

REFERENCES

1. Kesimpta® subcutaneous injection [prescribing information]. East Hanover, NJ: Novartis; April 2024.

HISTORY

Type of Revision	Summary of Changes	Review Date
Early Annual Revision	Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery. No criteria changes.	05/16/2023
Annual Revision	No criteria changes.	05/15/2024